**AUB KQ1 Evidence Table (Reference ID #1441)**

| **Study Description** | **Intervention(s)/ Comparator(s)** | **Patient Population** | **Baseline Measure(s)** | **Outcome Measure(s)** | **Overall Quality**  **Risk of Bias** |
| --- | --- | --- | --- | --- | --- |
| **Author:**  Protheroe et al., 2007  **Country:**  United Kingdom  **Enrollment** **period:**  July 2003 to January 2005  **Intervention** **setting:**  19 general practices  **Funding:**  Grant from Medical Research Council  **Author industry relationship disclosures:**  None  **Study Design:**  RCT  **Blinding:**  NR | **Intervention:**  Self-directed, interactive computerized decision aid (Clinical Guidance Tree) and patient information leaflet  Treatment options included watchful waiting, nonhormonal drug treatments (mefenamic acid, tranexamic acid, NSAIDS and ethamsylate), hormonal medications (COC and progestogens), LNG-IUS (Mirena) and surgical options (transcervical endometrial resection, abdominal or vaginal hysterectomy)    **Comparator:**  Control: Patient information leaflet alone  **Groups:**  **G1**: Decision aid  **G2**: Control  **Followup:**  6 months | **Inclusion criteria:**   * Aged 30-55 years * Menorrhagia and consulted their general practitioner in the previous week   **Exclusion criteria:**   * Heavy menstrual bleeding caused by physical pathology such as confirmed or provisional diagnosis of cancer, endometriosis, fibroids, polyps and cysts * Inability to understand English * Considered unsuitable by their general practitioner (including terminal illness, mental health problems)   **N at enrollment:**  **G1:** 74  **G2:** 72  **N at followup (%):**  **G1:** 60 (81)  **G2:** 56 (78)  **Age years, mean ± SD:**  **G1:** 41 ± 5.2  **G2:** 41 ± 5.4  **BMI:**  NR  **Parity:**  NR  **Race/ethnicity:**  NR  **Achieved higher education, n (%):**  **G1:** 17 (23)  **G2:** 15 (21) | Decisional Conflict Scale total score,b mean ± SD:  **G1:** 51 ± 20.6  **G2:** 50 ± 19.4  Spielberger State-Trait Anxiety Inventory score,c mean ± SD:  **G1:** 12.7 ± 4.2  **G2:** 13.4 ± 4.2  Menorrhagic Specific Utility Scale score,b mean ± SD:  **G1:** 36.2 ± 19.6  **G2:** 39.9 ± 21.8  Knowledge (% of correct answers), mean ± SD:  **G1:** 36.7 ± 18.8  **G2:** 36.5 ± 21.0  Baseline treatment preference, n (%):  Had a treatment preference at baseline:  **G1:** 47 (63)  **G2:** 45 (62)  Tablets:  **G1:** 20 (27)  **G2:** 22 (30.5)  Surgery:  **G1:** 22 (30)  **G2:** 18 (25)  Hormone intrauterine device:  **G1:** 5 (6.5)  **G2:** 5 (7)  Unsure:  **G1:** 27 (36.5)  **G2**: 27 (37.5) | Decisional Conflict Scale total scoreb at 2 weeks, mean ± SD:  **G1:** 23.4 ± 14.3 (n=69)  **G2:** 40.5 ± 18.3 (n=69)  **G1 vs. G2:** p<0.001  Decisional Conflict Scale total scoreb at 2 weeks, adjusted difference (95% CI):  **G1 vs. G2:** -16.6 (-21.5,  -11.7)  Spielberger State-Trait Anxiety Inventory score,c mean ± SD:  2 weeks:  **G1:** 11.6 ± 3.7 (n=59)  **G2:** 12.2 ± 3.7 (n=61)  **G1 vs. G2:** p=0.16  6 months:  **G1:** 11.2 ± 4.2 (n=47)  **G2:** 13.3 ± 4.9 (n=52)  **G1 vs. G2:** p=0.067  Spielberger State-Trait Anxiety Inventory score,c adjusted difference (95% CI):  2 weeks:  **G1 vs. G2:** -1.0 (-2.4, 0.4)  6 months:  **G1 vs. G2:** -1.8 (-3.7, 0.1)  Menorrhagic Specific Utility Scale score, mean ± SD:  **G1:** 59.3 ± 30.0 (n=60)  **G2:** 50.9 ± 25.1 (n=56)  **G1 vs. G2:** p=0.033  Menorrhagic Specific Utility Scale score, adjusted difference (95% CI):  **G1 vs. G2:** 10.9 (0.9, 21.0)  Knowledge (% of correct answers), mean ± SD:  **G1:** 59.7 ± 18.4 (n=54)  **G2:** 48.8 ± 19.6 (n=54)  **G1 vs. G2:** p=0.014  Knowledge (% of correct answers), adjusted difference (95% CI):  **G1 vs. G2:** 9.3 (1.9, 16.6)  **Bleeding:**  NR  **Quality of life:**  NR  **Pain:**  NR  **Sexual function:**  NR  **Patient satisfaction:**  NR  **Fertility:**  NR  **Time to conception:**  NR  **Additional interventions,**a **n (%):**  Treatment at 6 months:  **G1:** 40 (71)  **G2:** 45 (80)  **G1 vs. G2:** p=0.268  Treatment preference at two weeks:  **G1:** 49 (88)  **G2:** 38 (68)  **G1 vs. G2:** p=0.011  Post intervention preference matches treatment received:  **G1:** 23 (58) n=40  **G2:** 20 (44) n=45  **G1 vs. G2:** p=0.198  Hospital appointment:  **G1:** 19 (34)  **G2:** 21 (38)  **G1 vs. G2:** p=0.659  Surgical treatment:  **G1:** 7 (13)  **G2:** 3 (5)  **G1 vs. G2:** p=0.139  Mirena:  **G1:** 13 (23)  **G2:** 15 (27)  **G1 vs. G2:** p=0.625  Medical treatment:  **G1:** 20 (36)  **G2:** 27 (48)  **G1 vs. G2:** p=0.198 | **Overall quality:**  Poor  **Risk of bias:**  Randomization:  Low  Allocation concealment:  Low  Selective reporting:  Unclear  Blinding patients/personnel:  High  Blinding outcome assessment:  High  Incomplete outcome reporting:  Low  Other:  Unclear |

**Table Notes:** a For G1 and G2 total n=56 in each group unless otherwise noted; b Scale 0-100; c Scale 6-24, where higher score indicates higher anxiety.